{"DataElement":{"publicId":"6062356","version":"1","preferredName":"Docetaxel Total Cycle Complete Count","preferredDefinition":"A response used to indicate the numeric value for the absolute number of cycles of Docetaxel was administered to a patient.","longName":"6062351v1.0:2180126v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"6062351","version":"1","preferredName":"Docetaxel Total Cycle Complete","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)_Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","longName":"2867151v1.0:2738389v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2867151","version":"1","preferredName":"Docetaxel","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","longName":"C1526","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"691968AC-E917-10FC-E040-BB89AD434990","latestVersionIndicator":"Yes","beginDate":"2009-05-04","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-04","modifiedBy":"ONEDATA","dateModified":"2009-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2738389","version":"1","preferredName":"Total Cycle Complete","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.:An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.:Complete; having every necessary or normal part or component or step; or having come or been brought to a conclusion.","longName":"C25304:C25472:C25250","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BD1DA0-A076-041C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-31","modifiedBy":"ONEDATA","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6490B4FF-70E6-7E3B-E053-F662850AD28A","latestVersionIndicator":"Yes","beginDate":"2018-02-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-02-06","modifiedBy":"GARRIDOJ","dateModified":"2018-02-28","changeDescription":"Created for EA8153, 02/06/18 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180126","version":"1","preferredName":"Treatment Course Count","preferredDefinition":"the numeric value for the absolute number of cycles of treatment administered to a patient.","longName":"TX_CRSE_CT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3427397","version":"1","preferredName":"Course Count","preferredDefinition":"A period of protocol-prescribed activity or intervention.:To determine the number or amount of something; the result of this activity.","longName":"C25379:C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC684543-7086-9ED8-E040-BB89AD434CEC","latestVersionIndicator":"Yes","beginDate":"2012-03-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-03-29","modifiedBy":"ONEDATA","dateModified":"2012-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0F837FC-02E3-5B37-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-15","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-15","modifiedBy":"ALAIS","dateModified":"2012-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000584","version":"1","longName":"Prior Treatment","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Number of cycles of Docetaxel","type":"Preferred Question Text","description":"Number of cycles of Docetaxel","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64910D20-5A8B-0737-E053-F662850A38ED","latestVersionIndicator":"Yes","beginDate":"2018-02-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-02-06","modifiedBy":"GARRIDOJ","dateModified":"2018-02-28","changeDescription":"Created for EA8153, 02/06/18 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}